ClinicalTrials.gg
CompletedNCT07233070Updated Oct 20, 2026

HRS-7450 Injection Phase II Clinical Trial for Acute Ischemic Stroke.

A Phase 2 interventional study of HRS-7450 Injection and HRS-7450 Injection in Acute Ischemic Stroke, sponsored by Fujian Shengdi Pharmaceutical Co., Ltd.. Completed at 2 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Fujian Shengdi Pharmaceutical Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment

Updated Oct 20, 2026Now CompletedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
210
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 750 studies in Ischemic Stroke with a site in China — 377 open to participants now, 396 under way, 76 of them phase 3. Ischemic Stroke · China.

Enrollment
329th of 563
210 · median 266
Started
2025
with 106 others
Phase 2
71 of 750
29 open now
Registered
611th of 750
by date

Among the 750 studies in Ischemic Stroke with a site in China, this one is the 329th largest by enrollment of the 563 interventional ones that give a count, is one of 107 that started in 2025, is one of 71 in phase 2, and was the 611th registered.

Ischemic Stroke

2,619 studies on the registry are indexed under Ischemic Stroke; 978 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

377 of the 750 studies in Ischemic Stroke with a site in China are open now. Recruiting first, the newest first:

372 more — sign in →

All 377 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 662 Ischemic Stroke studies recruiting now, 396 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 26 take children under 18; 42 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 750 studies in Ischemic Stroke with a site in China, or all of them as a file.
02

Study summary

This study plans to enroll a total of 208 patients with Acute Ischemic Stroke (AIS) who present within 4.5 to 24 hours of symptom onset and meet the specified imaging criteria.

03

Conditions studied

  • Acute Ischemic Stroke

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Fully understand and voluntarily participate in this study, and sign the form;
  2. Aged between 18 and 80 years inclusive (18 ≤ age ≤ 80), regardless of gender;
  3. Onset of symptoms within 4.5 to 24 hours;
  4. Clinically diagnosed with acute ischemic stroke;
  5. Pre-stroke modified Rankin Scale (mRS) score \< 2;
  6. National Institutes of Health Stroke Scale (NIHSS) score between 6 and 25 (inclusive) at screening;
  7. Meet the imaging inclusion criteria;
  8. Female subjects of and male subjects with partners of childbearing potential must use highly effective and avoid sperm/ova donation.

Exclusion criteria

Exclusion Criteria:

  1. Treatment with thrombolytic therapy.
  2. Planned endovascular therapy.
  3. Arterial dissection of the head, neck, or aorta.
  4. Multiple infarctions across multiple large vascular territories.
  5. NIHSS level of consciousness item 1a score > 2.
  6. Neurological deficits presenting after a seizure or post-ictal state, or the presence of other neurological conditions leading to uncooperative or unwillingness to cooperate with examination.
  7. Hypodensity exceeding one-third of the middle cerebral artery (MCA) territory on non-contrast CT scan.
  8. Intracranial tumor, arteriovenous malformation (AVM), or giant aneurysm.
  9. History of intracranial hemorrhagic disease, including but not limited to intracerebral hemorrhage, subarachnoid hemorrhage, etc.
  10. History of ischemic stroke, severe head trauma, or intracranial/intraspinal surgery within the past 3 months.
  11. Visceral bleeding within the past 3 weeks, including but not limited to gastrointestinal or genitourinary bleeding.
  12. Major surgery or severe trauma within the past 2 weeks.
  13. Arterial puncture at a non-compressible site within the past week.
  14. Systolic blood pressure ≥180 mmHg and/or diastolic blood pressure ≥100 mmHg despite aggressive antihypertensive treatment.
  15. Known significant bleeding tendency or severe coagulation disorder.
  16. Blood glucose at screening >22.2 mmol/L or \<2.8 mmol/L; subjects may be re-evaluated after active treatment.
  17. Within the past 3 months: acute ST-segment elevation myocardial infarction (MI), and/or acute decompensated heart failure, and/or > 520 ms, and/or hospitalization for acute coronary syndrome, MI, cardiac arrest, or unplanned coronary intervention; or (NYHA) Class III/IV heart failure; or known ventricular tachycardia.
  18. Significant liver disease history, or and/or ALT and/or GGT ≥3 × , and/or total (TBIL) ≥2 × ULN, or known congenital disorder of bilirubin metabolism.
  19. severe renal disease, or estimated (eGFR) \<30 mL/min/1.73 m².
  20. History of hemolytic anemia due to various causes, currently under treatment or not meeting cure criteria.
  21. Known allergy or to HRS-7450 or any in its formulation.
  22. Treatment with therapeutic doses of heparin or low molecular weight heparin within 24 hours.
  23. Use of oral anticoagulants within 48 hours, including vitamin K antagonists, direct thrombin inhibitors, factor Xa inhibitors, or other anticoagulants.
  24. Use of glycoprotein IIb/IIIa receptor inhibitors within 48 hours.
  25. Female subjects who are pregnant or breastfeeding, or with a positive pregnancy test.
  26. Participation in another drug or device clinical trial within the 3 months prior to screening.
  27. Terminal illness with a of less than 1 year.
  28. Any other condition deemed by the investigator to make the subject unsuitable for participation in this trial.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
210 participants (actual)

Study arms

  • Experimental
    Treatment group A: HRS-7450 Injection

    Drug: HRS-7450 Injection

  • Experimental
    Treatment group B: HRS-7450 Injection

    Drug: HRS-7450 Injection

  • Experimental
    Treatment group C: HRS-7450 Injection

    Drug: HRS-7450 Injection

  • Placebo comparator
    Treatment group D: HRS-7450 Injection Placebo.

    Drug: HRS-7450 Injection Placebo

Interventions

  • DrugHRS-7450 Injection

    HRS-7450 Injection; low dose

  • DrugHRS-7450 Injection

    HRS-7450 Injection; Intermediate dose

  • DrugHRS-7450 Injection

    HRS-7450 Injection; high dose

  • DrugHRS-7450 Injection Placebo

    HRS-7450 Injection Placebo

06

What researchers measure

Primary outcomes

  1. mRS score of 0-1 at 90 days

    Time frame: within 90 days after the start of administration

Secondary outcomes

  1. Reperfusion rate at 24 hours;

    Time frame: within 24 hours after the start of administration

  2. Recanalization rate at 24 hours;

    Time frame: within 24 hours after the start of administration

  3. Proportion of subjects with ≥8-point reduction in NIHSS score or NIHSS score of 0-1 at 24 hours;

    Time frame: within 24 hours after the start of administration

  4. Infarct volume at 7 days;

    Time frame: within 7 days after the start of administration

  5. Proportion of subjects with ≥8-point reduction in NIHSS score or NIHSS score of 0-1 at 7 days;

    Time frame: within 7 days after the start of administration

  6. NIHSS score at 14 days;

    Time frame: within 14 days after the start of administration

  7. mRS score at 90 days;

    Time frame: within 90 days after the start of administration

  8. Proportion of subjects with mRS score 0-2 at 90 days;

    Time frame: within 90 days after the start of administration

  9. Incidence of symptomatic intracranial hemorrhage (sICH) within 36 hours after dosing;

    Time frame: within 36 hours after the start of administration

  10. Incidence of symptomatic intracranial hemorrhage (sICH) within 7 days after dosing;

    Time frame: within 7 days after the start of administration

  11. Incidence of intracranial hemorrhage (ICH) within 36 hours after dosing;

    Time frame: within 36 hours after the start of administration

  12. Incidence of intracranial hemorrhage (ICH) within 7 days after dosing;

    Time frame: within 7 days after the start of administration

  13. Incidence of major non-intracranial hemorrhage within 36 hours after dosing;

    Time frame: within 36 hours after the start of administration

  14. Incidence of major non-intracranial hemorrhage within 7 days after dosing;

    Time frame: within 7 days after the start of administration

  15. Mortality rate at 7 days after dosing;

    Time frame: within 7 days after the start of administration

  16. Mortality rate at 90 days after dosing;

    Time frame: within 90 days after the start of administration

07

Study locations

2 sites
  • The First Affiliated Hospital of Sun Yat-sen University
    Guangzhou, Guangdong 510062, China
  • Linyi People's Hospital
    Linyi, Shandong 276002, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2025 to primary completion in Sep 2026, 10 months.

Of 41 industry-sponsored phase 2 interventional studies under Ischemic Stroke, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 35. This study's 10 months is below that.

Counting every sponsor, half of 123 studies reached it within 28 months; a quarter within 15 and three quarters within 39.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: primary completion Oct 2026 → Sep 2026 and completion Jan 2027 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2025
First posted
Nov 18, 2025
StartActual
Oct 31, 2025
Primary completionActual
Sep 17, 2026was Oct 2026
CompletionActual
Sep 17, 2026was Jan 2027
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 20, 2026
Primary completion
Oct 2026→Sep 17, 2026 (actual)
Oct 20, 2026
Study completion
Jan 2027→Sep 17, 2026 (actual)
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Active, not recruiting→Completed
    Primary completion Oct 2026→Sep 17, 2026 (now actual)
    Study completion Jan 2027→Sep 17, 2026 (now actual)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07233070
Responsible party
Sponsor
First posted
Nov 18, 2025
Start date
Oct 31, 2025
Primary completion
Sep 17, 2026
Completion
Sep 17, 2026
Last update
Oct 20, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion